Atossa Therapeutics (ATOS) announced its strategic decision to pursue a metastatic breast cancer indication for (Z)-endoxifen. Atossa believes ...
Atossa Therapeutics, Inc. announced its decision to pursue a metastatic breast cancer indication for (Z)-endoxifen, a selective estrogen receptor modulator (SERM) that has demonstrated encouraging ...
SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company ...
Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...
Hosted on MSN1mon
Atossa Therapeutics faces patent setback, continues developmentSEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a biopharmaceutical company focusing on breast cancer treatment with a market capitalization of $107 million, has encountered a challenge in its ...
Read Our Latest Stock Report on ATOS Atossa Therapeutics Trading Down 1.1 % Shares of NASDAQ:ATOS opened at $0.77 on Thursday. The company has a 50 day moving average of $0.96 and a 200-day moving ...
SEATTLE – Atossa Therapeutics, Inc., a biopharmaceutical company with a market capitalization of $98.77 million, has been notified by The Nasdaq Stock Market LLC that it is currently not meeting the ...
SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company with a market capitalization of $93 million, announced today its strategic decision to focus on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback